Search PubMed⌕ Search

Biomedical subjects

J L Teruel

Publications and source records attributed to J L Teruel.

At least 19 recordsLinked to original sources
PubMed1999

Treatment of secondary hyperparathyroidism in hemodialyzed patients with high-dose calcium carbonate without vitamin D3 supplements.

BACKGROUND: Vitamin D compounds are usually indicated for the treatment of secondary hyperparathyroidism in dialysis patients. The possibility to induce a reversal of hyperparathyroidism with calcium supplementation alone is controversial. The present study was conducted to assess if oral calcium carbonate may constitute a therapeutic option for the control of hyperparathyroidism in patients with high PTH concentrations at the beginning of the treatment with chronic hemodialysis. METHODS: Thirty-one patients with end-stage renal failure with an intact PTH concentration above 250 pg/ml at the beginning of chronic hemodialysis therapy were treated with high doses of calcium carbonate; no patient received either aluminium-containing binders or vitamin D compounds. To minimize hypercalcemia, a calcium dialysate concentration of 2.5 mEq/l was used in all patients. The goal of the study was to reduce the intact PTH concentration to 250 pg/ml with oral calcium carbonate supplements alone. RESULTS: Throughout the first year on hemodialysis treatment, the intact PTH concentration decreased from 538 +/- 256 to 251 +/- 218 pg/ml (p < 0.001). By the end of the study, the therapeutic objective was achieved in 22 patients (71%) ('responder' group). The remaining 9 patients were classified as the 'treatment failure' group. The basal intact PTH concentration was not different between both groups (508 +/- 235 vs. 612 +/- 303 pg/ml, respectively, p = n.s.), but 5 'treatment failure' patients admitted to take a dose of calcium carbonate lower than that prescribed. There were 40 episodes of hyperphosphatemia (11% of all measurements) in 7 of 31 patients, 5 of them belonged to the noncompliance 'treatment failure' patients. Only 15 episodes (4% of all measurements) of transient hypercalcemia (range 11.1 - 11.9 mg/dl) were detected in 8 patients. CONCLUSIONS: Secondary hyperparathyroidism in hemodialysis patients can often be reverted by oral calcium carbonate alone. But a good adherence to treatment is absolutely necessary.

Administration, Oral↗
PubMed1999

Hepatitis E virus: relevance in blood donors and risk groups.

BACKGROUND AND OBJECTIVES: Hepatitis E virus (HEV) infection usually causes acute self-limited disease. HEV is associated with faecal-contaminated drinking water, but other vectors, such as blood, are possible. The aim of this study was to investigate the prevalence of HEV in blood donors and in two groups at high risk for parenteral infections, namely, haemodialysis patients, and children infected with HCV via blood transfusion. MATERIALS AND METHODS: We investigated the prevalence of anti-HEV in 863 blood donors, 63 haemodialysis patients, and 42 children infected post transfusion with HCV. RESULTS: The prevalence rates were 2.8, 6.3%, and zero, respectively. CONCLUSIONS: (1) The incidence of HEV in Spain is similar to that in other Western European countries, and (2) HEV is probably not transmitted parenterally to children.

Adolescent↗
PubMed1998

Delayed graft function does not reduce the survival of renal transplant allografts.

BACKGROUND: The aim of the present study was to investigate the effect of delayed graft function (DGF) in graft outcome when adjusted by the presence of acute rejection in the first month after transplantation. METHODS: A total of 437 cadaveric renal transplant patients on cyclosporine and steroids were included in the study. Variables related to donor, recipient, and graft were prospectively collected. RESULTS: The incidence of DGF was 44.4%. When patients dying with a functioning graft were censored, graft survival rates at 1 and 6 years were similar in patients with immediate function to those with DGF, when rejection was not present (96% and 81% vs. 95% and 83%, respectively). Rejection negatively influenced graft survival rates at 1 and 6 years, both in patients with immediate graft function (80% and 73%, P<0.05 vs. no DGF/no rejection) and more deeply in those with associated DGF (77% and 62%, P<0.001 vs. no DGF/no rejection). Rejection was more frequently diagnosed in patients with DGF than in those with immediate graft function (50% vs. 39.9%, P<0.05). Length of hospitalization was longer and the number of needle core biopsies was higher in patients with DGF or rejection. The presence of both complications had an additive effect. CONCLUSIONS: This study showed that DGF did not adversely affect kidney graft survival in patients without rejection. However, it increased the length of hospitalization and the number of graft biopsies, thus increasing the cost of transplantation. Moreover, rejection was more frequent in patients with DGF, and it had a negative impact on graft outcome. Because the association of DGF and rejection gave the poorest outcome, an effort should be made to prevent both complications.

Adolescent↗
PubMed1998

[Familial hypercholesterolemia: molecular identification and characterization of the first compound homozygote in Spain].

Homozygous familial hypercholestrolemia (FH) is a rare genetic disorder (one in 1 million persons) due to two different mutations in the LDL receptor gene (compound homozygous) or, rarely, to the presence of the same mutation in the two aleles. In these patients the absence of a functional LDL receptor produces extreme elevations of plasma cholesterol levels that need an aggressive and expensive treatment with LDL apheresis or hepatic transplantation. The clinical evolution is poor with early coronary heart disease. Molecular biology techniques allow a genetic diagnosis and a genetic counseling in the affected subjects. We have identified and characterized the first compound homozygous of FH in Spain using the single strand conformational polymorphism (SSCP) analysis. The patient is a 30 years old female, who carried two different mutations in the LDL receptor gene: the G528V and the D280G (a new mutation). These mutations produce significant changes in the aminoacid sequence and could be classified as class 2.

Adult↗
PubMed1998

Effect of different membranes on amino-acid losses during haemodialysis.

BACKGROUND: We analysed amino-acid losses during haemodialysis, their influence on plasma amino-acid concentration, and their possible effects on nutritional state. METHODS: Five patients were dialysed with three membranes: cuprophan (CUP), polysulphone (PS), and polyacrylonitrile AN69 (PAN). We compared anthropometric and biochemical parameters after 6 months in patients dialysed with CUP respect to patients with PAN. RESULTS: Total losses of amino acids were higher with PAN than with PS and CUP (6.1 +/- 2.3 vs 3.8 +/- 1.3, P < 0.05, and 3.7 +/- 1.3 g/session, P < 0.01 respectively). Losses of essential amino acids (EAA) and nonessential amino acids (NEAA) were also higher with PAN respect to PS and CUP (1.8 +/- 0.8 vs 1 +/- 0.3 and 0.8 +/- 0.3, and 4.3 +/- 1.6 vs 2.8 +/- 1 and 2.9 +/- 1.1 g/session, P < 0.05). The percentage reduction for plasma EAA and NEAA were lower with CUP respect to PS and PAN (11 +/- 5% and 20 +/- 14% vs 25 +/- 10% and 33 +/- 11%, and 30 +/- 11% and 25 +/- 17% respectively, P < 0.05). There was no difference in the nutritional state between patients with CUP and PAN. However, plasma valine in patients with PAN was lower than in those with CUP (1.88 +/- 0.12 vs 2.13 +/- 0.32 mg/dl) and almost reached statistical significance. CONCLUSIONS: New synthetic membranes are advantageous with respect to conventional ones, but a disadvantage is the higher amino-acid losses, especially with polyacrylonitrile. Long-term studies are necessary to evaluate the impact of amino-acid losses on nutritional state in patients dialysed with these membranes.

Adult↗
PubMed1998

Relationship between serum parathyroid hormone levels and lipid profile in hemodialysis patients. Evolution of lipid parameters after parathyroidectomy.

To determine the influence of parathyroid hormone (PTH) on lipid disturbances of uremia, the lipid profile was determined in 34 hemodialysis (HD) patients, comparing lipid parameters among subjects classified according to their intact PTH level. Furthermore, the effect of correction of severe secondary hyperparathyroidism on serum lipids was evaluated in 7 patients after parathyroidectomy. Total cholesterol, high-density lipoproteins (HDL), triglycerides, apolipoproteins A-I and B-100 (Apo B and Apo B), lipoprotein(a) and the ratios of cholesterol/HDL and Apo A/Apo B were analyzed. There was no correlation between serum lipids and PTH levels in the total group. Lipid profile was similar among patients classified according to their PTH level. No correlations were observed in either group between lipids and PTH. Lipid profile did not change in the seven patients with severe secondary hyperparathyroidism after parathyroidectomy. In conclusion, there was no relationship between PTH and lipids and risk ratios in HD patients. Lipid profile did not change in patients with severe secondary hyperparathyroidism after parathyroidectomy. These findings suggest that PTH does not play a significant role in the dyslipidemia of renal failure.

Adult↗
PubMed1998

Hepatitis E virus: relevance in blood donors and other risk groups.

BACKGROUND AND OBJECTIVES: Hepatitis E virus (HEV) infection usually causes an acute self-limited disease. HEV is associated with feces-contaminated drinking water, but other vectors, such as blood, are possible. The aim of this study was to investigate the prevalence of HEV in blood donors and in two groups at high risk of parenteral infections, namely, hemodialysis patients and children infected with hepatitis C virus (HCV) via blood transfusion. MATERIALS AND METHODS: We investigated the prevalence of anti-HEV in 863 blood donors, 63 hemodialysis patients, and 42 children infected with HCV posttransfusion. RESULTS: The prevalence rates were 2.8, 6. 3%, and 0 respectively. CONCLUSIONS: (1) The incidence of HEV in Spain is similar to that in other western European countries, and (2) HEV is probably not transmitted parenterally to children.

Adolescent↗
PubMed1997

Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients.

We have studied the changes in the lipid profile of 14 chronic hemodialysis patients receiving a 6-month cycle of nandrolone decanoate as treatment for anemia. Nandrolone decanoate was administered in a weekly intramuscular dose of 200 mg and resulted in an increase in the hemoglobin concentration (baseline, 7.9 +/- 0.9 g/dL; month 6, 10.8 +/- 1.7 g/dL; P < 0.001, ANOVA) and also produced relevant modifications in the lipid concentrations. The most significant finding was a decrease in the concentration of lipoprotein(a) [Lp(a)]: baseline, 19.8 mg/dL (median), month 2, 10.6 mg/dL; month 4, 8.7 mg/dL; and month 6, 7.1 mg/dL (P < 0.001, Friedman). Other lipid changes induced by nandrolone decanoate were an increase in the concentrations of apolipoprotein B (P < 0.02, ANOVA) and triglyceride (P = NS, ANOVA) and a decrease of high-density lipoprotein (HDL) cholesterol (P < 0.001, ANOVA) and apolipoprotein A-I (P = NS, ANOVA). The decrease in HDL cholesterol was at the expense of the HDL2 cholesterol subfraction, whereas HDL3 remained unchanged. These lipid modifications were reversible; 4 months after nandrolone decanoate withdrawal, the lipid concentrations were similar to the basal values. The changes in Lp(a) levels did not correlate with those of hemoglobin or the other lipid parameters, suggesting that the underlying mechanisms are unrelated. Our findings could be clinically relevant if confirmed by further studies.

Aged↗
PubMed1997

The impact of malnutrition in morbidity and mortality in stable haemodialysis patients. Spanish Cooperative Study of Nutrition in Hemodialysis.

BACKGROUND: When assessed by single biochemical measurements, malnutrition in dialysis patients is associated with increased mortality, but there are few data evaluating abnormalities in anthropometry or composite nutritional scores and outcome. The aim of our study was to ascertain the prevalence and severity of malnutrition in 761 stable patients from 20 haemodialysis centres and its influence in morbidity and mortality after one year of follow-up. METHODS: Malnutrition was estimated by scoring four anthropometric indexes; body mass index (BMI), triceps skinfold thickness (TSF), mid-arm circumference (MAC), and mid-arm muscle circumference (MAMC); three biochemical measurements; serum albumin, serum transferrin and total lymphocyte count; and clinical examination. Mortality and hospitalizations were collected prospectively during the year of follow-up. RESULTS: A moderate/severe degree of malnutrition was presented by 51.6% of male and 46.3% of female patients. TSF was moderate-severely decreased in 41% without differences between males and females. MAMC was moderately decreased in 19.8% of males and in 8.1% of females (P < 0.001). Multiple logistic regression analysis showed that the predictors of malnutrition were: age > 65 years (OR = 1.96, CI: 1.22-3.14), male sex (OR = 1.95, CI: 1.24-3.07), comorbidity index (OR = 1.23, CI: 1.03-1.45), time on dialysis (OR = 1.13, CI: 1.08-1.18), duration of dialysis (OR = 0.73, CI: 0.63-0.85) and PCR related to ideal body weight (OR = 0.17, CI: 0.06-0.50). After 1 year of follow-up, data from 442 patients were available. A total of 68 patients died (15.4%) with cardiovascular diseases being the most frequent cause of death (57.3% of the cases). The predictors of mortality were: age (OR = 1.06, CI: 1.03-1.09), cardiovascular disease (OR = 2.13, CI: 1.19-3.83), neurological disease (OR = 2.96, CI: 1.41-6.15), nephroangiosclerosis (OR = 2.34, CI: 1.10-4.98) and total lymphocyte count (OR = 0.93, CI: 0.87-0.98). Hospitalization was needed in 44% of patients. The comorbidity index, serum albumin and age were the predictive factors of hospitalization. CONCLUSIONS: Protein-calorie malnutrition is frequent in haemodialysis patients. Fat depletion predominated in both sexes. Duration of dialysis and protein catabolic rate related to ideal body weight was the only predictor which could be influenced by a nutritional intervention. Morbidity appeared to be influenced by the comorbidity index and age was the strongest predictor of mortality. The only nutritional measurements predictive of morbidity and mortality were serum albumin and total lymphocyte count respectively. Therefore, the influence of malnutrition in morbidity and mortality can not be definitively stated.

Adolescent↗
PubMed1997

Satisfactory control of secondary hyperparathyroidism with low-calcium dialysate in patients not receiving vitamin D.

The use of a dialysate calcium concentration of 2.5 mEq/1 for patients not receiving vitamin D is controversial. Therefore, it has been suggested that oral calcium supplements might be sufficient to avoid a negative calcium balance which could result in a worsening of secondary hyperparathyroidism. In order to clarify these aspects, we reduced the dialysis fluid calcium level in 26 patients on chronic hemodialysis with a dialysate calcium concentration of 3.25 mEq/l, all of them receiving low doses of calcium carbonate and aluminum hydroxide. No patient received supplements with vitamin D during the previous 2 years. These patients have been dialyzed using a dialysate calcium concentration of 2.5 mEq/l for 1 year. Gradually we increased the dose of calcium carbonate and decreased the dose of aluminum hydroxide to maintain the predialysis serum calcium and phosphate concentrations between 8-10 and 4-6 mg/dl, respectively. After 1 year of hemodialysis with a low-calcium dialysate (2.5 mEq/l), the oral dose of calcium carbonate was increased from 3.5 +/- 2.6 to 9.2 +/- 5.6 g/day (p < 0.001). In 22 patients (85%) the aluminum hydroxide was stopped, and in the remaining 4 cases the dose was lowered. The reduction in the dialysate calcium concentration did not increase the incidence of hypercalcemia or hyperphosphatemia. In the whole group, we did not observe a significant variation in the levels of intact parathyroid hormone (iPTH; 324 +/- 123 vs. 311 +/- 256 pg/ ml) or alkaline phosphatase (230 +/- 115 vs. 224 +/- 127 U/l), although there was a reduction in the serum aluminum concentration (33 +/- 31 vs. 21.8 +/- 20.2 micrograms/l; p < 0.001). We analyzed the evolution of iPTH in each case. In 15 patients (58%) the iPTH concentration decreased, in 6 cases (23%) it remained stable, and in only 5 subjects (19%) there was an increase (2 of them did not take the oral calcium dosage recommended). In conclusion, a low dialysate calcium concentration (2.5 mEq/l) is safe for most patients not receiving vitamin D. But adherence of patients to high doses of oral calcium supplements is absolutely necessary.

Adult↗